ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August9, 2017, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished under this Item 2.02 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or underthe Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
| Item 2.02 | Financial Statements and Exhibits. |
|
ExhibitNo. |
Description |
| 99.1 | Press release of Ardelyx, Inc. |
ARDELYX, INC. ExhibitEX-99.1 2 d414347dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results Restructuring Aligns Resources on Execution of Late-Stage Program Milestones T3MPO-2 Phase 3 Trial Results of Tenapanor for IBS-C on Track for Early Fourth Quarter; RDX7675 Onset-of-Action Data Planned for Fourth Quarter Conference Call to be Held at 8:00 a.m. ET Today FREMONT,…To view the full exhibit click here
About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.
